期刊文献+

长春瑞滨联合顺铂治疗晚期NSCLC 110例临床观察 被引量:12

Navelbine and cisplatin combined chemotherapy in the treatment of advanced non-small cell lung cancer
下载PDF
导出
摘要 目的 观察长春瑞滨 (NVB) +顺铂 (PDD)联合化疗方案治疗晚期非小细胞肺癌的疗效及毒副反应。方法 自 1998年至 2 0 0 2年对 110例中晚期NSCLC进行NVB +PDD联合化疗 ,NVB 2 5mg /m2 ,第 1,8天用。PDD 6 0 80mg /m2 分三天用 ,2 1天为一个周期 ,至少应用两个周期。结果 全组总有效率为 4 7.3% ,其中初治有效率为 4 8.7% ,复治有效率为 4 3.8%。IIIa期有效率为 5 2 .2 % ,IIIb期有效率为 5 3.1% ,IV期有效率为 4 1.8%。腺癌有效率为 5 2 .3% ,鳞癌有效率为 4 6 .7%。 (P >0 .0 5 )。化疗副反应主要是白细胞降低及静脉炎。白细胞下降占 93.6 % ,主要是I,II ,III度 ,分别为 32 .7% ,38.2 % ,18.2 %。静脉炎发生率为 14 .5 %。结论 NVB +PDD方案治疗NSCLC疗效较好 ,毒副反应较轻 ,可以耐受。 ObjectiveTo evaluate the efficacy and toxicity of combination chemotherapy with navelbine (NVB) and cisplatin (PDD) in the treatment of advanced non-small cell lung cancer (NSCLC). MethodsFrom 1998 to 2002, 110 patients with NSCLC were treated with NVB plus PDD.NVB was given at a dose of 25 mg /m 2 on day 1 and 8,PDD 60-80 mg /m 2 within 3 days. 21 days was one circle,with at least two circles. Results The overall response rate (RR)was 47.3%, 48.7% for the first treatment cases and 43.8% for the multi- treatment cases. RR of stage III_ a ,III_ b and IV was 52.2%,53.1% and 41.8% respectively. RR of adenocarcinoma and squamous cell carcinoma was 52.3% and 46.7% respectively (P>0.05).The common toxicities were myelosuppression and phlebitis. Drop of WBC accounted for 93.6% and phlebitis for 14.5%. Conclusion Combination chemotherapy with NVB and PDD is an effective method to treat advanced NSCLC, and toxicities are low.
出处 《肿瘤》 CAS CSCD 北大核心 2003年第3期243-244,共2页 Tumor
关键词 长春瑞滨 顺铂 治疗 晚期NSCLC 联合化疗 肿瘤 Non-small cell lung cancer Navelbine Cislatin Combination chemotherapy
  • 相关文献

参考文献3

二级参考文献3

共引文献27

同被引文献56

  • 1邓述恺,杨小琼,潘碧.异长春花碱致麻痹性肠梗阻1例及文献复习[J].河南肿瘤学杂志,2004,17(4):296-297. 被引量:2
  • 2李春艳,高燕,唐东霞,徐静.盖诺联合顺铂治疗恶性肿瘤近期疗效观察[J].肿瘤防治研究,2004,31(11):721-721. 被引量:1
  • 3康健,李龙芸,白春学,周彩存,罗永艾.肺癌非手术治疗的临床问题[J].中国实用内科杂志,2005,25(8):693-699. 被引量:5
  • 4潘启超.长春碱类的新进展──失碳长春碱[J].癌症,1996,15(3):228-231. 被引量:276
  • 5Crawford J. Update: Vinorelbine(Navelbine) in non - small cell lung cancer[J]. Semin Oncol, 1996,23(2) :2-7.
  • 6Burger RA, DiSaia PJ, Roberts JA, et al. Phase Ⅱ trial of vinorelbine in recurrent and progressive epithelial ovarian cancer[J]. Gynecol Oncol,1999, 72(2): 148-153.
  • 7Furuse K, Kubota K, Kawahara M, et al. A phase Ⅱ study of vinorelbine, a new derivative of vinca alkaloid for previously untreated advanced non - small cell lung cancer[J]. Lung Cancer, 1994, 11(5 - 6) :385 -391.
  • 8SocinskiNA. Cytotoxic chemotherapy in advanced non small cell lung cancer:a review of standard treatment paradigms[J]. Clin Cancer Res,2004,10(12 pt 2):4210-4214.
  • 9CrinoL,CappuzzoF.Gemcita bineinnon small cell lung cancer[J]. Expert Opin Phamacother,2002,3(6):745-753.
  • 10[5]Gregory RK,Smith IE.Vinorelbine - a clinical review[J].Br J Cancer,2000,82(12) :1907 ~ 1913.

引证文献12

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部